One-Visit HPV test and treatment could slash cervical cancer in poorer nations

NCT ID NCT05133661

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether it's practical and acceptable to offer HPV testing and immediate treatment for precancerous cervical lesions in the same visit. It involves over 17,600 women in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines. The goal is to see if this integrated approach can be rolled out widely to help eliminate cervical cancer in low- and middle-income countries.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HPV testing and thermal ablation of precancerous lesions
What this could lead to
If successful, this approach could make cervical cancer screening and treatment more accessible in low-resource settings, moving the world closer to eliminating cervical cancer.
What could go wrong
This is an implementation study, not a test of a new drug or vaccine. It measures feasibility and acceptability, not long-term cancer prevention. Results may not apply to all regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CMA de Do

    Ouagadougou, Burkina Faso

  • FSU Koko

    Bouaké, Côte d’Ivoire

  • Metro-Manila

    Quezon City, Philippines, 1103, Philippines

  • Quetzaltenango

    Quetzaltenango, Guatemala

More trials for these conditions

Other studies related to the condition(s) this trial covers.